PPARG and bipolar disorder: Peroxisome-proliferator-activated-receptor-γ (PPAR-γ) agonism shows parallel promise: a double-blind trial of pioglitazone (15–45 mg) in bipolar depression improved depressive symptoms and normalised inflammatory markers relative to placebo [134].